Oral health crucial for preventing nonventilator hospital-acquired pneumonia, study says

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-08-08 12:00 GMT   |   Update On 2022-08-08 12:07 GMT

USA: A recent study published in Infection Control & Hospital Epidemiology supports the emerging body of evidence on the cruciality of oral health for the prevention of nonventilator hospital-acquired pneumonia (NVHAP). Research stated that preventive dental treatment within 12 months or periodontal therapy in the 6 months prior to hospitalization is associated with a reduced NVHAP...

Login or Register to read the full article

USA: A recent study published in Infection Control & Hospital Epidemiology supports the emerging body of evidence on the cruciality of oral health for the prevention of nonventilator hospital-acquired pneumonia (NVHAP). Research stated that preventive dental treatment within 12 months or periodontal therapy in the 6 months prior to hospitalization is associated with a reduced NVHAP risk. 

Hospital-acquired pneumonia is the leading cause of hospital-acquired infections, and NVHAP comprises of 60% of the cases. NVHAP is prevalent in ∼1 in 100 hospitalized patients with an associated crude mortality rate of 15% to 30% and is associated with intensive care unit utilization rates and antibiotic usage. It is the most common pathway to sepsis. Despite the known harm, not much is known about ways to prevent NVHAP.

Because most pneumonia starts from germs in the oropharyngeal cavity, it seemed logical that access to dental services could also impact the cases of nonventilator hospital-acquired pneumonia. 

Against the above background, Dian Baker, School of Nursing, California State University–Sacramento, Sacramento, California, and colleagues aimed to determine whether utilization of dental services prior to hospitalization is associated with a decreased risk of NVHAP in 2019 cross-sectional study.

For this purpose, the researchers analyzed hospital records for Medicaid beneficiaries who acquired nonventilator hospital-acquired pneumonia. 

Key findings include:

· 13.7% (N = 13,866) of the 1,012,025 Medicaid beneficiaries admitted to the hospital for ≥2 days in 2019 were diagnosed with NVHAP, with incidence rates of 1.95 per 1,000 patient days and 121.9 per 100,000 Medicaid participants.

· NVHAP occurred in across sociodemographic groups.

· Predicted probability of diagnosis of NVHAP decreased with each additional preventive dental visit 1 year prior to hospitalization. In our adjusted model, beneficiaries who had at least 1 preventive dental visit within a year of hospitalization were 10% less likely to get NVHAP (adjusted odds ratio [aOR], 0.90), compared to beneficiaries with no preventive dental visits or visits >1 year prior to hospitalization.

·The use of periodontal services (SRP) <6 months prior to hospitalization decreased the odds of NVHAP diagnosis by 30% (aOR, 0.70).

· Receipt of SRP 6–12 months (aOR, 0.85) or 1–2 years prior to hospitalization (aOR, 0.96) showed no impact on NVHAP incidence. 

The researchers wrote, "a Medicaid beneficiary receiving preventive dental treatment in the year prior, or periodontal therapy in the 6 months prior to hospitalization, is associated with a reduced NVHAP risk."

"These findings support the emerging body of evidence on the importance of oral health for NVHAP prevention," they concluded. 

Reference:

Baker, D., Giuliano, K., Thakkar-Samtani, M., Scannapieco, F., Glick, M., Restrepo, M., . . . Frantsve-Hawley, J. (2022). The association between accessing dental services and nonventilator hospital-acquired pneumonia among 2019 Medicaid beneficiaries. Infection Control & Hospital Epidemiology, 1-3. doi:10.1017/ice.2022.163


Tags:    
Article Source : Infection Control & Hospital Epidemiology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News